论文部分内容阅读
目的探讨卡比多巴-左旋多巴控释片治疗帕金森病合并睡眠障碍患者的疗效。方法应用卡比多巴-左旋多巴控释片治疗46例帕金森病合并睡眠障碍患者,分别于治疗前后连续2次全夜PSG监测,取第2晚PSG结果进行比较,对比治疗前后全PSG监测参数、PQSI评分及ESS评分,评定UPDRS-Ⅲ评分及H&Y分期评分的改变。结果治疗后ESS评分、UPDRS-Ⅲ评分明显下降(P﹤0.05);而PQSI评分、H&Y分期评分、卧床时间、总睡眠期变化、总睡眠时间、睡眠潜伏期、睡眠效率、微觉醒指数、睡眠中觉醒次数、入睡后觉醒时间、S1(min)、S2(min)、S3+S4(min)、REM(min)、S1(%)、S2(%)、S3+S4(%)、REM(%)均差异无统计学意义(P﹥0.05)。结论卡比多巴-左旋多巴控释片既可改善帕金森病运动症状又能改善患者日间嗜睡状态,同时具有改善帕金森病患者夜间睡眠质量的趋势。
Objective To investigate the curative effect of carbidopa-levodopa controlled release tablets in patients with Parkinson’s disease complicated with sleep disorders. Methods 46 patients with Parkinson’s disease complicated with sleep disorders were treated with carbidopa-levodopa controlled-release tablets. Two consecutive nighttime PSG monitoring were performed before and after treatment. The PSG results at the second night were compared and compared before and after treatment Monitoring parameters, PQSI score and ESS score, to assess UPDRS-Ⅲ score and H & Y staging score changes. Results After treatment, the scores of ESS and UPDRS-Ⅲ decreased significantly (P <0.05). However, the score of PQSI, H & Y staging, bed rest time, total sleep duration, total sleep time, sleep latency, sleep efficiency, arousal index, The number of awakenings, awakening time after falling asleep, S1 (min), S2 (min), S3 + S4 (min), REM (min), S1 ) Were no significant difference (P> 0.05). Conclusion The controlled release of carbidopa-levodopa can both improve the symptoms of Parkinson’s disease and improve the daytime sleepiness in patients with Parkinson’s disease, and improve the quality of sleep in patients with Parkinson’s disease at night.